Clinical trials: Heart Failure (HF)
Heart Failure, NYHA Class III Heart Failure
NORM-HF Pivotal Study
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF…
- Conditions
- Heart Failure, NYHA Class III Heart Failure, NYHA Class II Heart Failure
- Trial name
- NORM-HF (NCT07574593)
- Testing
- IVC Sensor
- Where
- 25 sites in United States
- Volunteers
- 800 people
- Sponsor
- Foundry Innovation & Research 1, Limited (FIRE1)
Heart Failure
CARE-HF Long Term Follow-up
The CARE-HF long-term follow-up trial evaluates the effects of cardiac resynchronization (CR) therapy on the mortality of patients from the CARE-HF program for an additional 4 year follow-up.
- Trial name
- NCT00318357
- Testing
- Continuation of CRT, Upgrade to CRT
- Where
- United Kingdom
- Volunteers
- 309 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Systolic
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes…
- Trial name
- PROVIDE-HF (NCT03387163)
- Testing
- Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients
The objective of the study is to determine if there is any relationship between respiratory rate and Heart Failure events.
- Trial name
- CORRELATE-HF (NCT00758121)
- Testing
- Cardiac Resynchronization Therapy Defibrillator
- Where
- 2 sites in United States, Belgium
- Volunteers
- 56 people
- Sponsor
- Boston Scientific Corporation
Heart Failure (HF)
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.
- Trial name
- HATS-OFF (NCT04149743)
- Testing
- Standard of Care with Hemotag
- Where
- 2 sites in United States
- Volunteers
- 420 people
- Sponsor
- Aventusoft, LLC.
Cardiorenal Syndrome
Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF)
The Cardiorenal Syndrome during Acute decompensated heart failure (ADHF) with persistent congestion despite high dose IV diuretic therapy is associated with remarkable morbidity, which can include the need for renal dialysis or…
- Trial name
- VOID-HF (NCT04227977)
- Testing
- JuxtaFlow System
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- 3ive Labs
Acute Decompensated Heart Failure
DORAYA-HF Early Feasibility Study
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05206422
- Testing
- Doraya Catheter
- Where
- 14 sites in United States
- Volunteers
- 21 people
- Sponsor
- Revamp Medical Inc.
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Heart Failure NYHA Class III
Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
Cardiac Heart Failure Questionnaire HF-Q) to assess the severity of the symptoms of Heart Failure. In this study, modified and translated, the "four-point" questionnaire by Severo and his associates - Heart Failure Questionnaire…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class IV
- Trial name
- THETIS (NCT03947853)
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure NYHA Class II
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF < 50%…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- BENEFIT-HF (NCT07232030)
- Testing
- Barostim System, Usual care medical management
- Where
- 22 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- CVRx, Inc.
Heart Failure (HF)
Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date…
- Trial name
- NCT02127307
- Where
- United States
- Volunteers
- 964 people
- Sponsor
- GE Healthcare
Heart Failure
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality.
- Trial name
- EVOLUTION-HF (NCT05635331)
- Where
- 16 sites in Greece
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
NYHA Class III Heart Failure
Correlation of SOZO BIS Measures With CardioMEMS PA Pressure
This study aims to establish the degree to which change in the ratio of ECF to TBW measured using the SOZO BIS device correlates with change in end-expiratory end-diastolic PAP measured using the CardioMEMS HF System (St.
- Trial name
- NCT02939053
- Testing
- SOZO
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- ImpediMed Limited
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 213 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure
Remote Speech Analysis in HF Patients Undergoing Haemodialysis
This is an observational, non-interventional, prospective, single-arm, open study for database establishment for R\&D purposes. The study will be conducted in 1 site in Israel with up to fifty (50) patients.
- Trial name
- NCT03714126
- Testing
- Cordio Medical
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Cordio Medical
Chronic Heart Failure
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
- Trial name
- NCT03388593
- Testing
- rhNRG-1
- Where
- 65 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Extended IASD Investigation: REDUCE LAP-HF IV
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients…
- Trial name
- NCT04632160
- Testing
- IASD System II
- Sponsor
- Corvia Medical
Heart Failure
REDUCE LAP-HF RANDOMIZED TRIAL I
A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure.
- Trial name
- NCT02600234
- Testing
- Inter-Atrial Shunt Device, Intracardiac Echo
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 44 people
- Sponsor
- Corvia Medical